Climate Capital Bio

Backing founders building bio-tech climate solutions that accelerate the decarbonization of the largest and least sustainable sectors of the economy.

Led by Michael Luciani and Jenny Kan

Click here to learn more

Sustainable cement, next generation plastics, alternative protein sources, textiles made from manufactured spider silk, mushroom leather – these are just a fraction of the promise of biotechnology. The bioeconomy has created new opportunities to support a more sustainable future and address the existential threats posed by climate change. We’re working to maximize the benefits of the bioeconomy, which has the potential to revitalize U.S. manufacturing, create more resilient supply chains and new jobs, address economic inequity, and reduce dependence on fossil fuels.

  • Founding partner of Climate Capital Bio and of the Climate Capital Syndicate. Michael is also a founding member of Terra Do’s Climate for Venture Investors program and mentors hard science climate-tech startups via the Maryland Energy Innovation Accelerator and biotech startups via Indie Bio.

    Previously the founder and CEO of The Tuesday Company, which was acquired by Helm (led by Emma Bloomberg). Tuesday pioneered the field of ‘relational organizing,’ creating two consumer-facing products with over 1M users. Prior to Tuesday, Michael worked on Hillary Clinton’s presidential campaign and in the Obama White House.

    After the acquisition of The Tuesday Company, Michael was able to combine his experience as a founder with his passions for frontier tech and climate to help early stage founders succeed.

    LinkedIn

  • Founding partner of Climate Capital Bio and technical due diligence lead. Jenny holds a Ph.D. from Cambridge in Chemistry. She was the lead protein engineer in the lab of Frances H. Arnold (2018 Nobel Laureate in Chemistry) at CalTech and worked with startups and Fortune 500 companies such as Dow Chemicals, L’Oreal, and Merck to use biology to solve problems and launch products. Jenny is the inventor of 7 patents, author of 24 peer-reviewed research articles, and invited speaker at Stanford, Berkeley, and MIT. Her synthetic biology research was previously featured in Forbes, The New York Times, and the Nobel Prize lecture.

    Prior to Climate Capital Bio, Jenny co-founded Simpl.Care, a venture-backed health tech startup, and worked at 17 Asset Management where she designed financial products and built ecosystems for underrepresented entrepreneurs. She mentors biotech startups at Nucleate, iGEM EPIC, and Indie Bio.

    LinkedIn

Climate Capital Bio Fund Portfolio

  • Wild Microbes (Making bio-production more scalable)

  • Pomodyne (Growing fruit without plants)

  • BioDrive (Enabling the targeted expression of specific traits in specific organisms)

  • CacheDNA (Room temperature DNA & RNA data storage)

  • Prism Bio (Decarbonizing and detoxifying the dying process) 

GP’s Prior Investments

Food & Ag

Chemicals

Minerals & Metals

Platforms & Infrastructure

Materials